Nonetheless, PD-1 and PD-L1 inhibitors are currently approved only for cancer immunotherapy owing to encouraging treatment results obtained from clinical trials, but not for chronic HIV infections [33,34,35]. Here, PDCD1 is linked to HIV infectious disease.